{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 43,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a structured layout to categorize achievements into three main pillars: COVID-19 vaccine, pipeline expansion, and corporate updates.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/8",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.18,
        "w": 0.72,
        "x": 0.24,
        "y": 0.195
      },
      "kind": "list",
      "text": "COVID-19 vaccine: Shipped >1 billion doses, signed contracts for 2.2 billion, committed 2 billion to low/middle income nations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d69859d8-289e-4101-b4f5-d7bb0fcc662a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.22,
        "w": 0.72,
        "x": 0.24,
        "y": 0.43
      },
      "kind": "list",
      "text": "Continued pipeline expansion: Randomized Phase 2 trial starts (BNT111, BNT113, BNT122) and First-in-Human Phase 1 trial starts (BNT211, BNT221, BNT151/2/3).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ed577911-91eb-42b4-a80a-dd33d4f2ad24",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.72,
        "x": 0.24,
        "y": 0.7
      },
      "kind": "list",
      "text": "Further corporate updates: Reported Q2 revenues of €5.3 billion, new CFO appointment, and acquisition of TCR platform/manufacturing facility.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f4724f81-b5f4-4158-a289-6734e46169f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.18,
        "x": 0.05,
        "y": 0.485
      },
      "kind": "paragraph",
      "text": "Second Quarter 2021 Highlights",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34c87b53-0d17-4777-9b6e-8f20f3ae44aa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.08,
        "y": 0.925
      },
      "kind": "source-note",
      "text": "As of July 21, 2021: includes doses shipped by collaboration partner Pfizer; s.t., solid tumors;",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34c32a25-ea1a-4a70-9360-0be9b540c3af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Strong Performance in the First Half of 2021",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e57fe4f-6ddf-4a69-9886-4c57c6f78b71",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 9,
      "from": 6,
      "beatId": "0c80980f-bde4-4a5a-b70b-8de7645c97f1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents the current situation and challenges in the immunotherapy space",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}